Grifols secures marketing licence for Flebogamma DIF

Grifols has secured the Australian marketing licence for Flebogamma DIF, an intravenous immunoglobulin (IVIG).

The Spanish holding company has plans to begin selling the product in Australia from next year, people looking for science sales jobs may be interested to know.

One of the highest per capita rates of IVIG consumption in the world is to be found in the country – and Grifols intends to establish itself in the plasma products market as part of its international expansion plans.

Flebogamma DIF (Double Inactivation and Filtering) is, according to the company: "The only polyvalent IVIG on the market whose production process includes two specific inactivation stages together with nanofiltration at 20 nanometres, significantly increasing its safety margin."

The product – which has been marketed in the US since last year – is currently being manufactured in Barcelona but Grifols has started work on a new plant in Los Angeles.

Grifols works in 90 countries across the world.